INTRODUCTION
============

Neurons communicate with others to form network in the brain through the release and detection of neurotransmitters. Many receptors participate in the detection of neurotransmitters including ionotropic receptors which mediate fast responses and metabotropic receptors which induce slow and long-term plasticity regulations. Metabotropic glutamate receptors (mGluRs), which are activated by glutamate, the major excitatory neurotransmitter of the central nervous system (CNS), consist of eight subtypes named from mGluR1 to mGluR8 show different localization and signaling in synapse ([@B50]). Other receptors such as serotonin receptors and dopamine receptors, which are activated by serotonin or dopamine, also have several variants ([@B55]). However, as the main inhibitory neurotransmitter in the CNS, gamma aminobutyric acid (GABA) has only one metabotropic receptor subtype, GABA~B~ receptor ([@B49]; [@B8]; [@B62]). Located both pre-synaptically and post-synaptically, GABA~B~ receptor is thought to play a role in CNS disorders such as epilepsy, spasticity, schizophrenia, anxiety, depression, cognitive deficits, and addiction ([@B9]). It is also shown to be involved in cell survival, nerve growth cone guidance, migration and position of neurons ([@B99]; [@B64]; [@B102]). How one GABA~B~ receptor induces multiple downstream functions remains to be discussed. Here, we show how multiple functions can be generated from a single GABA~B~ receptor through: (1) the oligomeric state in dimers or larger complexes; (2) subunit and isoform variants; (3) cell surface expression and localization; (4) crosstalk with other receptors GABA~B~ receptor interacting proteins.

DIMERIZATION AND LARGE OLIGOMIZATION OF GABA~**B**~ RECEPTOR
============================================================

As a member of GPCR class C, GABA~B~ receptor consists of two subunits: GABA~B1~ and GABA~B2~, and functions as a heterodimer ([@B49]; [@B62]). As shown in **Figure [1](#F1){ref-type="fig"}**, each subunit is composed of a large extracellular domain (Venus flytrap, VFT), a seven-transmembrane domain, and an intracellular C-terminal. Although GABA~B2~ shares 54% similarity with GABA~B1~, only the VFT domain of GABA~B1~ can bind ligands (such as GABA and baclofen) and orthosteric antagonists (such as CGP54626, CGP64213; [@B74]; [@B38]; [@B37]). Due to the presence of endoplasmic reticulum (ER) retention sequence (RSRR) in the C-terminal, GABA~B1~ cannot reach the plasma membrane by itself. GABA~B2~ masks GABA~B1~ ER retention sequence via a coiled-coil domain to escort GABA~B1~ to the cell surface ([@B34]). GABA~B2~ ectodomain does not bind GABA, but interacts with the GABA~B1~ ectodomain to increase agonist affinity by stabilizing the agonist-bound conformation of GABA~B1~([@B57]; [@B79]; [@B38]). GABA~B2~ is also responsible for G protein coupling ([@B29]; [@B43]). Following activation of G~i/o~ protein, G~αi/o~ subunits inhibit adenylyl cyclase to reduce cAMP levels while G~βγ~ subunits inhibit Ca^2+^ channels and activate K^+^ channels ([@B16]; [@B95]; [@B21]).

![**Structure organization of GABA~**B**~ receptor.** GABA~B~ receptor forms heterodimer composed by GABA~B1~ and GABA~B2~. GABA~B1~ is responsible for ligand binding in N-terminal VFT domain, whereas the VFT of GABA~B2~ fails to bind any known ligand. PAMs bind to GABA~B2~ transmembrane domain to potentiate the effect of agonist.](fphar-05-00012-g001){#F1}

Up to now, baclofen is the only drug targeting GABA~B~ receptor in the market, which is used as a muscle relaxant to treat spasticity ([@B33]). Positive allosteric modulators (PAMs), such as CGP7930 and GS39783, bind within GABA~B2~ transmembrane domain to strengthen the effect of agonists ([@B96]). CGP7930 acts as a PAM and partial agonist through GABA~B2~ which can facilitate agonist response at low concentration and activate the receptor alone at higher concentration ([@B96]; [@B69]; [@B13]; [@B92]).

Dimers, tetramers, or higher order oligomers of GABA~B~ receptor can be detected both in heterologous system ([@B63]; [@B18]) and in native neurons ([@B84]; [@B23]). GABA~B~ receptor is present in equilibrium between heterodimers and higher-order oligomers, with a relative preference for tetramers (dimers of dimers) and octamers (tetramers of dimers; [@B18]). Whereas GABA~B~ receptor heterodimers are stable due to strong non-covalent interactions, the higher-order oligomers are the result of weaker and likely transient interactions among heterodimers ([@B18]). Although agonist stimulation did not alter receptor di-/oligomerization ([@B18]), destabilizing the oligomers by a competitor or a GABA~B1~ mutant revealed different G protein coupling efficiencies depending on the oligomeric state of the receptor ([@B22]), suggesting a negative functional cooperativity between the GABA~B~ receptor heterodimers within the large oligomers.

GABA~**B**~ RECEPTOR SUBUNITS AND ISOFORMS
==========================================

The GABA~B~ receptor subunits GABA~B1~ and GABA~B2~ are co-expressed throughout the brain ([@B9]; [@B58]; [@B10]). GABA~B1~ knock-out mice displayed seizures, hyperalgesia, hyperlocomotion, memory impairment, anxiety, and immobility decrease ([@B82]; [@B80]; [@B20]) while inactivation of the GABA~B2~ induced similar phenotype ([@B66]). Both the GABA~B1~ and GABA~B2~ subunits are essential for normal function of GABA~B~ receptor. However, baclofen was able to inhibit K^+^ channels in the CA1 pyramidal neurons of GABA~B2~^-/-^ mice ([@B36]), suggesting specific properties of GABA~B1~ in the absence of GABA~B2~. Mutation of the GABA~B1~ ER retention sequence RSRR to ASAR allows GABA~B1~ to reach the cell surface by itself ([@B25]). GABA~B~ receptor agonist, baclofen, could induce ERK phosphorylation in cerebellar granule cells and HEK cells overexpressed GABA~B1~ and GABA~B2~ ([@B92]). The GABA~B1~-ASAR mutant could also increase ERK phosphorylation through G~βγ~ in the absence of GABA~B2~ ([@B3]). Although only GABA~B2~ was reported to be important for G~i/o~ coupling, G~βγ~ were found to pre-couple to C-terminal of GABA~B~ for presynaptic inhibition ([@B53]). These observations suggested the direct coupling from GABA~B1~ to G protein signaling. On the other hand, GABA~B2~ alone co-precipitated and co-expressed with M~2~ muscarinic receptor (M~2~R) in cortical neurons. Co-expression of the GABA~B2~ rescued internalization of M~2~R and desensitization of GIRK channels induced by chronic stimulation ([@B17]). Since GABA~B1~ and GABA~B2~ do not always exhibit the same expression pattern ([@B10]), the interaction between M~2~R and the GABA~B2~ provides a possible mechanism for signaling induced by GABA~B2~ alone. Overall, though it is well accepted GABA~B1~ and GABA~B2~ form a functional receptor together, it is still possible that each subunit plays individual roles, no matter when they act in heterodimer or alone.

Furthermore, 14 isoforms of the GABA~B1~ can be generated by differential transcription or splicing of the mRNA named from GABA~B1a~ to GABA~B1n~ ([@B9]). GABA~B1a~ and GABA~B1b~ are the most abundant isoforms expressed in brain ([@B8]). GABA~B1c~ has a single sushi-domain and widely expressed in brain and form functional receptors in HEK cells co-expressed with GABA~B2~ ([@B73]). GABA~B1e/g/h/i/j/l/m/n~ do not have transmembrane domains. Been secreted, GABA~B1e~ strongly interacted with GABA~B2~ and disturbed normal GABA~B1~/GABA~B2~ association, but failed to disrupt G-protein coupled inwardly rectifying potassium activation ([@B83]). Purified sushi domains of GABA~B1j~ could impair the inhibitory effect of GABA~B~ heteroreceptors on evoked and spontaneous glutamate release ([@B91]). GABA~B1g/h/i~ show similar sequence with GABA~B1j~ containing the sushi domains followed by a unique C-terminal sequence ([@B47]), but the function remains to be detected. The inhibitory effect of GABA~B~ heteroreceptors-induced potassium current was also found in GABA~B1l~ and GABA~B1m~, but not for GABA~B1k~ ([@B54]). Other isoforms like GABA~B1d/f~ were mostly detected in transcription expression profile and no function was confirmed yet ([@B47]). GABA~B1a~ and GABA~B1b~ are well studied compared with others. GABA~B1a~ has two additional sushi domains in the N-terminal region, compared with GABA~B1b~ ([@B14]). Due to the presence of these sushi domains, GABA~B1a~ preferentially targets to the axon terminals of excitatory synapses. Post-synaptically, both isoforms were found in dendrites, but only GABA~B1b~ could localize in spine heads ([@B98]; [@B11]). GABA~B1b~ was responsible for mediating postsynaptic inhibition of Ca^2+^ spikes, whereas presynaptic inhibition of GABA release was mediated by GABA~B1a~ ([@B71]). GABA~B1a~, but not GABA~B1b~, was involved in impaired synaptic plasticity in hippocampus long-term potentiation ([@B98]), emphasizing the molecular differences in synaptic GABA~B~ functions. GABA~B1a~ and GABA~B1b~ also contributed differentially to GABA~B~ receptor-mediated cognitive processes such as spontaneous alternation, object recognition and passive avoidance ([@B46]). Till now, no difference has been shown on molecular pharmacology between GABA~B1a~ and GABA~B1b~ ([@B12]). However, CHOP was found to subtype-selective interact with GABA~B1a~ but not GABA~B1b~ and reduced GABA~B1a~/GABA~B2~ receptor cell surface expression ([@B81]), suggesting the functional diversity mediated by GABA~B1a~ and GABA~B1b~ through different protein-protein interactions.

GABA~B~ RECEPTOR CELL SURFACE EXPRESSION AND LOCALIZATION
=========================================================

Control of cell surface GABA~B~ receptor expression plays an important role in the regulation of receptor efficacy. GABA~B~ receptor cell surface expression is remarkably stable and baclofen treatment did not elicit conventional β-arrestin recruitment ([@B27]; [@B31]). However, GABA~B~ receptor undergoes rapid constitutive receptor internalization ([@B41]). The balance between sorting and degradation after internalization and rapid recycling process maintains its cell surface expression stability ([@B40]). Phosphorylation of serine892 in the C-terminus of GABA~B2~ is important for cell surface expression stability. Chronic agonist stimulation de-phosphorylates serine892 in GABA~B2~ and decreases GABA~B~ receptor cell surface expression ([@B27]; [@B31]). The interaction between endogenous protein Mupp1 and GABA~B2~ also plays a role to maintain GABA~B~ receptor membrane stability ([@B1]).

Lipid rafts are specialized microdomains compartmentalize cellular processes by serving as organizing centers for the assembly of signaling molecules to regulate signal transduction. The GABA~B~ receptor and its downstream effectors, G~αi~ and G~αo~ proteins, are all localized in lipid rafts ([@B7], [@B6]). Interestingly, GABA~B~ receptors exhibited a lower GTPγS response to agonist binding in raft-enriched fractions than in whole membranes ([@B6]), suggesting that changes in membrane environment may regulate its function. Activation of 5-HT~1a~ receptor could target it to lipid rafts and facilitated receptor-mediated signal transduction ([@B77]), whereas mu-opioid receptor agonists promoted receptor exiting from lipid rafts ([@B101]). Examination of the dynamic lateral diffusion of GABA~B~ receptors at the cell surface revealed restricted mobility of GABA~B2~. After activation by baclofen, levels of the mobile fraction were significantly increased ([@B76]). Furthermore, by using single-molecule analysis of fluorescently labeled GPCR revealed that larger oligomers of GABA~B~ receptor were prevalently organized into ordered arrays ([@B18]). Agonist stimulation increased the mobility of large oligomer of GABA~B~ receptor on the cell surface ([@B18]). These data suggested the possibility of GABA~B~ receptor mobility between lipid raft and non-lipid raft domains. Given that the level of cell surface GABA~B~ receptors is highly stable following activation, lateral diffusion of GABA~B~ receptor might provide another mechanism for controlling its signal strength.

CROSSTALK OF GABA~**B**~ RECEPTOR WITH OTHER RECEPTORS
======================================================

GABA~**B**~ AND GABA~**A**~ RECEPTORS
-------------------------------------

Both receptors are located pre-synaptically and post-synaptically. GABA~A~ receptors are Cl^-^ ion channels which produce fast electrical signals, whereas GABA~B~ receptor induced long-term modulation through G protein-regulated gene transcription and protein synthesis ([@B59]). Crosstalk between them was identified in several cell types. Due to variants of GABA~A~ receptor subtype in different neurons, GABA~B~ receptor showed multiple functions. In developing hypothalamic neurons, GABA~B~ receptor activation can depress GABA~A~ receptor-mediated Ca^2+^ rise by both reducing the synaptic release of GABA presynaptically and decreasing the postsynaptic Ca^2+^ responsiveness ([@B68]). In dentate gyrus granule cells, GABA~B~ receptors showed remarkable distribution overlap with GABA~A~ receptor on post-synaptic dendritic and somatic membranes. GABA~B~ receptors enhanced tonic inhibition induced by extrasynaptic GABA~A~ receptor ([@B89]). This was also observed in ventrobasal thalamus and cerebellar granule cells, but absent in CA1 pyramidal cells or layer 2/3 cortical pyramidal neurons ([@B24]; [@B89]). One explanation is that postsynaptic GABA~B~ receptor is possible to preferentially modulate δ--type subunit containing GABA~A~ receptor which is dominant in dentate gyrus granule cells, compared with α5--type subunit containing GABA~A~ receptor, which is expressed in CA1 pyramidal cells ([@B19]; [@B39]). The γ2 subunit of GABA~A~ was found to interact with GABA~B~ receptors and regulate GABA~B~ receptor internalization ([@B2]). On the other hand, activation of GABA~B~ receptor promotes GABA~A~ receptor cell surface expression through increasing secreting brain-derived neurotrophic factor (BDNF) and PLC/DAG/PKC activation ([@B51]). The crosstalk between GABA~B~ and GABA~A~ receptors shows possibility for drug co-application in disease treatment. In animal model, co-application of both of their agonists: muscimol and baclofen protected hippocampal CA1 neurons in cerebral ischemic injury ([@B100]). Tiagabine and vigabatrin which increase GABA level in the brain and affect both GABA~B~ and GABA~A~ receptor activity, are effective in treating alcohol addiction ([@B94]).

GABA~**B**~ RECEPTORS AND mGluR1s
---------------------------------

Metabotropic glutamate receptors 1 also belongs to GPCR class C as GABA~B~ receptor. It is coupled to G~q~ protein to increase IP3 production and Ca^2+^ flux when activated by glutamate ([@B61]). Both receptors exhibited a high co-localization in the dendritic spine of Purkinje cells ([@B48]; [@B78]) and co-immunoprecipitated from brain lysates ([@B88]), but no oligomerization of GABA~B~ receptor and mGluR1a was observed ([@B78]), suggesting the existence of a GABA~B~-mGluR1 receptor complex but no direct physical contact. GABA~B~ receptor enhanced the long-term depression of a glutamate-evoked current and increased the magnitude of depression in cerebellar parallel fiber--Purkinje cell synapses ([@B48]). PLC, G~αi/o~ and G~βγ~ subunits was involved in GABA~B~ receptor potentiated mGluR1 signaling ([@B78]). Baclofen regulated mGluR1-current was concentration dependent: a low concentration of baclofen showed augment effect while higher concentration showed inhibition ([@B44]). The crosstalk was also related to mGluR1a receptor expression: more potentiation by GABA~B~ receptor when mGluR1a receptors were less expressed ([@B78]). It suggests a precise control of two receptors for the balance of neuronal inhibition and activation. The crosstalk between G~i/o~-coupled and G~q~-coupled receptors which is independent of direct interaction was also observed in other receptors such as mGluR1a and mGluR2 or GABA~B~ and 5-HT~2c~ receptor ([@B78]). The co-compartmentalization of these receptors and other scaffold proteins like G proteins, homer to assemble in platforms ensures the crosstalk specificity ([@B15]).

GABA~**B**~ AND NMDA RECEPTORS
------------------------------

Gamma aminobutyric acid(B) receptor cell surface expression is independent of agonist stimulation but controlled by glutamate. Application of glutamate, mainly through NMDA receptor, decreased GABA~B~ receptor cell surface expression and GABA~B~ receptor activated K^+^ channel current ([@B42]; [@B60]; [@B90]). Activated by NMDA receptors, CaMKII can directly interact with and phosphorylates serine867 in the C-terminus of GABA~B1~ to trigger GABA~B~ receptor endocytosis ([@B42]). CaMKII might be a key signal molecular to modulate the crosstalk between GABA~B~ receptor signaling and glutamate signaling as CaMKII was shown to interact with the NMDA receptor and regulate NMDA receptor controlled plasticity ([@B5]; [@B30]). Upon NMDA receptor activation, the phosphorylation of serine783 in GABA~B2~ was increased by AMP-dependent protein kinase ([@B90]). Furthermore, both presynaptic and postsynaptic GABA~B~ receptor can regulate NMDA-mediated excitatory currents ([@B67]; [@B87]). Baclofen improved NMDA hypofunction-related social function and spatial memory deficient in knockout mice model ([@B35]), suggesting the crosstalk between GABA~B~ and NMDA receptors in two directions.

GABA~**B**~ AND TYROSINE KINASE RECEPTORS
-----------------------------------------

The transactivation of GPCR to RTK is an important signaling pathway which contributes to growth promotion activity ([@B28]). GABA~B~ receptor could trigger secretion of BDNF and subsequent activation of the BDNF-related kinase TrkB receptor signaling pathway to promote the development of GABAergic synapses which is called ligand-dependent transactivation ([@B32]). GABA~B~ receptor could transactivate insulin-like growth factor-1 (IGF-1) receptor to induce Akt phosphorylation and protect cerebellar granule cells from apoptosis. This was independent of ligand IGF-1 ([@B93]). The first mechanism leads to the RTK activation in cells surrounding the activated GPCR due to a diffusion of the ligand, whereas the second mechanism is mediated by intracellular event that is limited to the signaling protein complex dynamically regulated upon receptor activation. G~i/o~ proteins were found to be pre-associated with the GABA~B~ receptor. Upon activation, the G~αi/o~ and G~βγ~ subunits were released from GABA~B~ receptor, followed by recruitment of FAK1, IGF-1 receptor, and Akt to GABA~B~ receptor. FAK1 played a key role in coordinating this dynamic process. This dynamic of the GABA~B~ receptor-associated complex is critical for signaling transduction and transactivation-dependent neuronal survival ([@B56]). Other RTKs such as epidermal growth factor receptor, neurotrophin receptor, platelet derived growth factor receptor, and fibroblast growth factor receptor have been investigated for other GPCRs ([@B70]; [@B86]). Whether GABA~B~ receptor transactivates other RTKs remains to be identified.

GABA~**B**~ RECEPTOR INTERACTING PROTEINS
=========================================

The intracellular GABA~B~ receptor interacting proteins are involved in GABA~B~ receptor functions such as cell surface expression (e.g., CHOP, MUPP1) ([@B81]; [@B1]), desensitization (e.g., GRK4, NSF) ([@B72]; [@B75]) and signaling transduction (e.g., G proteins, ATF4, FAK1) ([@B97]; [@B56]). Several new proteins have been identified recently to modulate GABA~B~ receptor heterodimer function. 14-3-3ς interacting with GABA~B1~ coiled-coil domain can partially bind to GABA~B1~ coiled-coil domain and disrupt association of GABA~B1~/GABA~B2~ heterodimers ([@B26]). Disruption of 14-3-3ς/GABA~B1~ interaction provides a strategy to enhance the effect of antinociceptive drugs ([@B52]). The potassium channel tetramerization domain-containing (KCTD) protein family members KCTD8, KCTD12, KCTD12b, and KCTD16 are tightly associated with the C-terminus of GABA~B2~ as auxiliary subunits in tetramers ([@B4]; [@B84]). This co-assembly changes the properties of the GABA~B1~ and GABA~B2~ core receptor in a KCTD subtype-specific manner. KCTD16 and KCTD8 led to persistent inhibition of Ca~v~ channels activity, whereas KCTD12 and KCTD12b receptors transiently decreased Ca~v~ channels activity ([@B84]; [@B85]). Except regulating agonist potency and kinetics, KCTD12 reduced constitutive receptor internalization to increase the magnitude of receptor signaling ([@B45]). The expression levels of individual KCTD transcripts vary during postnatal brain development. KCTD12 and KCTD16 are widely expressed in most neurons whereas KCTD8 and KCTD12b show a restricted expression pattern ([@B65]). The distinct spatial and temporal KCTD distribution patterns might underlie functional differences in native GABA~B~ receptor responses.

CONCLUSION
==========

In all, we summarize how one single GABA~B~ receptor generates multiple functions through the following aspects: (1) the composition of tetramer and large oligomer increased the complexity of the receptor; (2) Variants of subunits and isoforms contribute to functional diversity. Differential compartmentalization of the receptor variants participate in distinct function; (3) Cell surface expression and localization in lipid raft are involved in regulating receptor signaling efficacy; (4) Novel functions are generated through crosstalk with interacting proteins, auxiliary subunits or other membrane receptors as shown in **Figure [2](#F2){ref-type="fig"}**. The observation of the complexity generated from a single GPCR such as GABA~B~ receptor will provide new strategy for drug development.

![**Schematic presentation of GABA~**B**~ receptor interacting proteins and crosstalk of GABA~**B**~ receptor with other receptors.** GABA~B~ receptor interacting proteins are binding to the C-terminus of GABA~B~ receptor modulating the receptor membrane expression (e.g., CHOP, MUPP1), desensitization (e.g., GRK4, NSF), signaling transduction (e.g., G proteins, ATF4) and diverse function (e.g., 14-3-3ς, KCTD8, KCTD12, KCTD12b, and KCTD16). At the membrane, GABA~B~ receptors have crosstalk with other receptors such as GABA~A~ receptor, mGluR1, NMDA receptor, TrkB receptor and IGF-1 receptor. Both heterodimers and tetramers of GABA~B~ receptors exist at the membrane. Dimers and dimers of GABA~B~ receptors form tetramers through GABA~B1~ and GABA~B1~ interaction.](fphar-05-00012-g002){#F2}
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